![]()
|
Report Date : |
27.11.2007 |
IDENTIFICATION
DETAILS
|
Name : |
OMAN PHARMACEUTICAL PRODUCTS CO. LLC |
|
|
|
|
Registered Office : |
Ajay Ent Building, Way No. 5229, Al Wadi Al Kabir, PO Box 54 & 1885 Muscat 113 |
|
|
|
|
Country : |
Sultanate of Oman |
|
|
|
|
Date of Incorporation : |
21.08.2001 |
|
|
|
|
Com. Reg. No.: |
2152460 |
|
|
|
|
Legal Form : |
Limited Liability Company |
|
|
|
|
Line of Business : |
Producers of Pharmaceutical Preparations |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
US $ 200,000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
SUMMARY
Company Name : OMAN PHARMACEUTICALS PRODUCTS CO LLC
Country of Origin : Sultanate of Oman
Legal Form : Limited Liability Company - LLC
Registration Date : 21st August 2001
Commercial Registration Number : 2152460
Membership Number : 244
Issued Capital : RO 150,000
Paid up Capital : RO 150,000
Total Workforce : 250
Line of Business : Producers of pharmaceutical preparations.
Financial Condition : Undetermined
Payments : Nothing detrimental uncovered
COMPANY NAME
OMAN PHARMACEUTICALS PRODUCTS CO LLC
ADDRESS
Registered & Physical Address
Location : Ajay Ent Building, Way No. 5229, Al Wadi Al Kabir
PO Box : 54 & 1885
Town : Muscat 113
Country : Sultanate of Oman
Telephone : (968-24) 502415 / 502315 / 815486
Facsimile :
(968-24) 502297 / 815490
Email : ajayentp@omantel.net.om
Premises
Subject operates from a large suite of offices that are rented and located in the Central Business Area of Muscat.
Branch Offices
Subject has a factory located in Salalah.
KEY PRINCIPALS
Name Nationality Position
Abdullah Abbass Bin Ahmed Omani Managing Director
Sujay Hamla Indian Director
Rajendra H Bhandari - General Manager
Berjall Mafwanai - Factory Manager
LEGAL FORM &
OWNERS
Date of Establishment : 21st August 2001
Legal Form : Sharikat Thet Massouliya Mahdoudeh (Limited Liability Company - LLC)
Commercial Reg. No. : 2152460
Membership No. : 244
Issued Capital : RO 150,000
Paid up Capital : RO 150,000
Name of Shareholder
(s)
Abdullah Abbass Bin Ahmed
Sujay Hamla
Non Omani Participation
The participation of non-Omani nationals in a trade or business in Oman is governed by the Foreign Business Investment Law, which sets capital requirements and requires 35 % Omaniparticipation in capital and profits.
Note to the Legal Form
The Limited Liability Company (LLC), or private company, is the form of business entity usually chosen by foreign investors. It may be formed by a minimum of 2 and a maximum of 30 natural or legal persons, whose liability is limited to their shares in the company’s capital. The minimum capital of a Limited Liability Company with foreign ownership should be RO 150,000, although this may be reduced to a minimum of RO 30,000 with the approval of the Minister of Commerce and Industry. For a company wholly owned by Omani nationals, the minimum capital is RO 10,000.
Contributions to capital may be made in cash of kind. Capital may not be increased by public subscription. The full amount of the share value must be paid in on subscription. Shares may not be assigned to a non-member, unless the other existing members are granted a pre-emptive right to purchase the shares.
LINE OF BUSINESS
Operations :
Engaged in the production of pharmaceutical preparations.
Subject is regulated by the Gulf Council Commission Drug Regulators.
Subject has a workforce of approximately 250 employees.
FINANCIAL HIGHLIGHTS
Companies registered in Oman are not legally required to make their accounts public and no financial information was released by the company or submitted by outside sources.
BANKERS
Commercial Bank of Dubai
Baniyas Street
PO Box : 1709
Deira
Dubai
Tel : (971-4) 2227121 / 2253222
Fax : (971-4) 2220943 / 2254565
PAYMENT HISTORY
No complaints regarding subject’s payments have been reported.
GENERAL COMMENTS
Established in 2001, subject is involved in the production of pharmaceutical preparations.
During the course of this investigation nothing detrimental was uncovered regarding subject’s operating history or the manner in which payments are fulfilled. As such the company is considered to be a fair trade risk.
Maximum suggested credit figure: US$ 200,000
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)